Background-In heart failure (HF) with reduced ejection fraction, randomized trials of statins did not demonstrate improved outcomes. However, randomized trials may not always be generalizable. The aim was to determine whether statins are associated with improved outcomes in an unselected nationwide population of patients with HF with reduced ejection fraction overall and in relation to ischemic heart disease (IHD). Methods and Results-In the Swedish Heart Failure Registry, 21 864 patients with HF with reduced ejection fraction (age ± SD, 72±12 years; 29% women), of whom 10 345 (47%) were treated with statins, were studied. Propensity scores for statin use were derived from 42 baseline variables. The associations between statin use and outcomes were assessed with Cox regressions in a population matched 1:1 based on propensity score and age and in the overall population with adjustment for propensity score and age. The primary outcome was all-cause mortality; secondary outcomes were cardiovascular mortality; HF hospitalization; and combined all-cause mortality or cardiovascular hospitalization. Survival at 1 year in the matched population was 83% for statin-treated versus 79% for untreated patients (hazard ratio, 0.81; 95% confidence interval, 0.76-0.86; P<0.001). In the unmatched population, 1-year survival was 85% for statin-treated versus 79% for untreated patients, hazard ratio after adjustment for propensity score and age was 0.84 (95% confidence interval, 0.80-0.89; P<0.001). No examined baseline variables interacted with statin use except for IHD (P=0.001), with a hazard ratio of 0.76 (95% confidence interval, 0.70-0.82, P<0.001) with IHD and 0.95 (95% confidence interval, 0.85-1.07; P=0.430 without IHD. Statin use was also associated with reduced risk for all 3 secondary outcomes. Conclusions-In an unselected nationwide population of patients with HF with reduced ejection fraction, statins were associated with improved outcomes, specifically in the presence of IHD. This contrasts with previous randomized controlled trials. Additional randomized controlled trials with more generalized inclusion or focused on IHD may be warranted. (Circ Heart Fail. 2015;8:252-260.
I schemic heart disease (IHD) is a major contributor to hospitalization and mortality in the Western hemisphere. 1, 2 Treatment with 3-hydroxy-3-metylglutaryl coenzyme A reductase inhibitors (statins) reduce total cholesterol and low-density lipoprotein, and also increase high-density lipoprotein. 3, 4 Although benefits of statin treatment have been demonstrated in many patient groups, the strongest documentation and the greatest benefits are in IHD. Effects include not only reduction of all-cause and cardiovascular mortality but also of cardiovascular events [5] [6] [7] [8] and reduced new onset heart failure (HF) after myocardial infarction. [9] [10] [11] Pleiotropic effects may include antifibrotic and antihypertrophic effects, upregulation of endothelial NO production, vasodilation and decreased platelet aggregation, 12 inhibition of inflammatory cytokines and neurohormonal activation, and reversal of myocardial remodeling. [13] [14] [15] [16] However, effects in HF with reduced ejection fraction (HFREF) are more controversial, [17] [18] [19] and the randomized Controlled Rosuvatatin Multinational Trial in Heart Failure (CORONA) and Gruppo Italiano per lon Studio della Sopravvivenza Nell Insufficienza Cardia (GISSI) did not demonstrate benefits of statins. 20, 21 
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Although randomized controlled trials (RCTs) are the gold standard for assessing treatment effects, they may have limited generalizability. Rigorous observational studies may add information about treatment patterns and associations with outcomes in unselected patients and real-world situations. Furthermore, the extensive evidence and recommendations for statins in IHD may provide a conundrum for clinicians in interpreting the absence of benefit in HFREF RCTs. Therefore, we tested the hypothesis that statins are associated with improved outcomes in an unselected nationwide population of patients with HFREF and assessed a potential interaction with IHD.
Methods
The Swedish Heart Failure Registry (RiksSvikt) has been previously described. 22 Inclusion criteria are clinician-judged HF. Echocardiography is overwhelmingly performed with standardized and accredited protocols requiring Simpson and M-mode determination of EF, but in this nationwide registry, EF is not independently adjudicated and we cannot rule out that some EF values are by visual estimation. In the registry, ≈80 variables are recorded at discharge from hospital or after outpatient clinic visits on a case record form and entered into a central web-based database. The database is run against the Swedish death registry, monthly. The protocol, registration form, and annual report are available at www.rikssvikt.se. The establishment of the registry and this study were approved by a multisite Ethics Committee and conform to the Declaration of Helsinki. Individual patient consent was not required, but the patients were informed of entry into national registries and allowed to opt out.
Mortality was determined from the Population Registry, causes of death from the Cause of Death Registry, and hospitalization from the Patient Registry. For cardiovascular mortality and hospitalization, we included ICD-10 diagnoses I00-I99; and for HF hospitalization, ICD-10 diagnoses I50, I42-I43, I25.5, I11.0, I13.0, and I13.2 were included. For ischemic hospitalization, ICD-10 diagnoses I20-I25.2 were included. The causes of death are based on death certificates, with potentially limited reliability. A recent study suggests a 55% accuracy of death certificates in cardiovascular disease in a Swedish community. 23 However, causes of hospitalization are more reliable. The positive predictive value for most hospitalization diagnoses in the Patient Registry is 85% to 95%, 24 and a HF diagnosis was verified in 86% to 91% of HF hospitalizations. 25 Between May 11, 2000 and April 23, 2012, 73 392 registrations were obtained in the registry from 66 of 77 hospitals and 97 of 1011 primary healthcare centers in Sweden. Registrations with statin use missing, EF ≥40% or EF missing, inclusions before January 1, 2001 or after December 31, 2011, and repeat registrations for the same patients were excluded, yielding 21 864 patients with HFREF (flow chart, Figure 1 ).
Statistical Analysis
Descriptive data are presented as numbers (n) and percentages or means with SD or median with interquartile range (IQR) as appropriate and compared with Student unpaired t tests or χ 2 tests as appropriate.
Propensity Scores
Propensity scores for treatment with statins were estimated for each patient by logistic regression with 42 clinically relevant baseline variables as independent variables and statin treatment as the dependent variable. All continuous variables were modeled using restricted cubic splines (3 degrees of freedom). The propensity score is the propensity from 0 to 1 to receive treatment, given a set of known variables, and is used to adjust for potential selection bias, confounding and differences between treatment group in observational studies. 26, 27 Missing values were handled by estimating 1 logistic regression model for each pattern of missing values. Each individual then received the propensity score that incorporated all variables with nonmissing values for that individual. An age-and propensity score-matched population was constructed 28 with matching 1:1 without replacement, based on age difference ≤5 years and propensity score difference ≤0.1. This yielded 5381 patients in each group (Figure 2 ).
Outcomes
The primary outcome, all-cause mortality, by statin treatment was assessed in the overall population with Kaplan-Meier analyses and plotted in the same figure as Kaplan-Meier survival for the matched population ( Figure 3 ). Cox regression models were used to estimate the hazard ratio (HR) and corresponding 95% confidence interval (CI) in the overall population, crude and adjusted for propensity score as a continuous covariate, as well as in the matched population. The proportional hazards assumption was tested by scaled Schoenfeld residuals and the presence of extreme outliers were assessed by dfbetas. No violations to the proportional hazards assumption or possibly influential outliers were found.
Interactions between statin therapy and clinically relevant variables were modeled with Cox regression and presented in a Forest plot for all-cause mortality for the matched population ( Figure 4 ). Continuous variables were dichotomized for visual interpretation. Interaction analyses render similar results as subgroup analyses with the additional benefit of being able to statistically test for differences in associations between statin use and outcomes between subgroups.
The secondary outcomes namely cardiovascular mortality; HF hospitalization; and combined all-cause mortality or cardiovascular hospitalization were also assessed with Cox regression in the matched population. Patients not experiencing an event were censored at December 31, 2011. In addition, for the end point cardiovascular mortality and HF hospitalization, censoring also occurred if the patient died from any other cause.
For all analyses, the level of significance was set to 5%, and all reported P values are 2-sided. Statistics were performed in R v 2.15.3 (R foundation for Statistical Computing, Vienna, Austria).
Results

Study Population
Baseline characteristics of the overall and matched study populations are presented in Table 1 . A total of 21 864 patients with HFREF, age 72±12 years, 29% female, were included. Overall, 47% were treated with statins. There were several differences between the groups. Treated versus untreated patients were of similar age but were more commonly men and with diabetes mellitus and with higher EF. However, the greatest difference was presence of IHD, in 74% of treated versus 35% of untreated patients. Also, statin-treated patients were more commonly on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and β-blockers (Table 1 ). Thus, in Table 1 , there are considerable standardized differences in baseline variables and in Figure 2 , an imbalance in propensity scores between the groups.
After propensity score and age matching, the standardized differences were small, although diabetes mellitus and IHD remained slightly more common in the treated group and EF was slightly lower in the untreated group (Table 1) , and propensity scores were now nearly identically distributed ( Figure 2 ).
Outcomes
Primary Outcome: All-Cause Mortality
In the overall population, survival was at 1, 3, and 5 years, 85%, 68%, and 53% in treated versus 79%, 61%, and 48% in untreated patients (Figure 3 ), crude HR 0.80 (95% CI, 0.76-0.83; P<0.001; Tables 2 and 3 ). . Forest plot illustrating hazard ratios for all-cause mortality associated with statin use in predefined subgroups in the matched population after adjustment for the interaction between statin use and the variable on the y axis. Note: Squares represent the hazard ratio and the lines represent the 95% confidence interval (CI). Continuous variables were analyzed as such but dichotomized at clinically relevant cutoffs for display in this figure. BMI indicates body mass index; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; NYHA, New York Heart Association functional class; and RAS, renin-angiotensin system.
Table 1. Baseline Characteristics of the Unmatched and Matched Populations of the Study Population Containing Participants With Heart Failure and Ejection Fraction <40%
Variables
No. ACEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker; BMI, body mass index; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HF, heart failure; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; NYHA class, New York Heart Association functional class; Standardized difference, the difference between the means for the 2 groups divided by the mutual SD.
Missing
Mean arterial pressure: derived as systolic blood pressure × one-third plus diastolic blood pressure × two thirds. Column no. indicates the variables included in the derivation of the propensity score. * P<0.05. In the matched population, the corresponding figures at 1, 3, and 5 years were 83%, 65%, and 53% versus 79%, 58%, and 45%, matched HR 0.81 (95% CI, 0.76-0.86; P<0.001; Tables 3  and 4 ). In the overall population, HR after adjustment for propensity score and age was 0.84 (95% CI, 0.80-0.89; P<0.001; Table  3 ). The hypothetical number needed to treat for 1 year to prevent 1 death from any cause was 25 (95% CI, 24.4-25.6) patients.
Interaction Analysis for All-Cause Mortality
In Figure 4 , a Forest plot illustrates the association between statin use and all-cause mortality in subgroups after adjustment for interactions between prespecified clinically important variables and statin treatment. There were no interactions except for a highly significant interaction with IHD (P=0.001); with HR of 0.76 (95% CI, 0.70-0.82; P<0.001) with IHD and 0.95 (95% CI, 0.85-1.07, P=0.430) without IHD. In contrast, there was no interaction with diabetes mellitus.
Secondary Outcomes
For the propensity score and age-matched population, HRs for the secondary outcomes are listed in Table 3 . Statin use was associated with reduced risk for all 3 secondary outcomes, ie, cardiovascular mortality, HF hospitalization, and composite all-cause mortality or cardiovascular hospitalization.
Discussion
In this large prospective registry of patients with HREF, use of statins was associated with reduced all-cause mortality, cardiovascular mortality, HF hospitalization, and the combined outcome of all-cause mortality and cardiovascular hospitalization. Our findings were consistent, both in a matched population based on propensity score and age and the overall population with adjustment for propensity score and age. Importantly, there was a strong interaction with IHD, where statin treatment was associated with reduced all-cause mortality in patients with but not without IHD. There was no interaction with diabetes mellitus.
Two major RCTs in HFREF 20, 21 have failed to show a benefit from statins. Therefore, our observational findings should be interpreted with caution and by no means should dictate care in any way. However, our study raises important questions and sheds light on (1) statin use and associations with outcomes in an unselected community population in contrast to RCT populations and (2) lends strength to the notion that statins are associated with benefit in IHD, possibly also in the presence of HFREF.
How to Interpret Our Results in Relation to the Literature
The discrepancy in our study versus RCTs may have numerous explanations. Rosuvastatin, studied in CORONA and GISSI-HF, is hydrophilic and relies on active transport into hepatocytes, whereas, for example, simvastatin and atorvastatin are lipophilic and may be expected to reach higher levels so that it could be expected that the levels of those statins are higher in the myocardial tissue. 29, 30 This may be particularly important because a potential mechanism of benefit may be regulation of cardiac inflammation rather than systemic lipid levels. Indeed, in a recent meta-analysis of 13 RCTs evaluating lipophilic statins in HFREF, Liu et al 31 demonstrated decreased mortality, and hospitalization in the statin treatment groups. We do not have information on specific statins used in our patients. However, the Swedish National Board of Health and Welfare maintains annual prescription data. Overall in Sweden, filled statin prescriptions per 1000 inhabitants were distributed as follows: in 2006 hydrophilic statins: rosuvastatin 4; pravastatin 11; fluvastatin 2; and lipophilic statins: simvastatin 206; atorvastatin 40. The corresponding figures for 2013 were as follows: rosuvastatin 13; pravastatin 6; fluvastatin 0.09; simvastatin 285; atorvastatin 66. Lovastatin is not available in Sweden. Thus, lipophilic statins were indeed overwhelmingly used in Sweden overall and most likely in our patients.
Conceivably, RCTs may have failed to demonstrate the benefit of statins because of inadequate power or less relevant end points. Indeed, HF hospitalization was not an end point, but in a post hoc analysis of CORONA, the cumulative number of hospitalizations (which is increasingly being used as an end point to enrich HF trials) were significantly reduced by 15% to 20%. 32 Interestingly, in a post hoc analysis of the Treating to New Target (TNT) study (high-versus low-dose atorvastatin in IHD), the higher dose resulted in lower risk of HF hospitalization overall, and in particular in patients with pre-existing HF, suggesting a potential direct effect on HF 11 . This could support the argument that statins might affect the development of HF. RCTs provide better evidence for a treatment effect in comparison with observational studies but may have other limitations. Older patients 28, 33, 34 and women 33, 35 are consistently excluded both in cardiovascular and cancer trials, potentially compromising external validity of RCTs. 33 Patients with HF included in RCTs may have been more ill and cared for by HF specialists active in HF trials, whereas patients with milder HF and predominantly IHD may have been cared for by general cardiologists or those practicing predominantly in the ischemia field. Indeed, in CORONA patients were more severely ill than in our study (eg, 60% versus 40% in NYHA class III), at a later stage of HF where the ability of the statins to modify the disease may be limited. There are additional indications that the populations differed (Table 5) , with patients in our study more frequently women, with more impaired left ventricular function, atrial fibrillation, and beta blocker treatment and less dilated cardiomyopathy, hypertension, and digitalis treatment than in RCTs.
Additional observational studies in HFREF suggest risk reduction for all-cause mortality associated with statin use. 36 In a propensity-scored matched analysis, including HFREF, Ouzounian et al 34 reported reduced all-cause mortality associated with statin use, however only, like in our study, in those with IHD. The same was reported about hospitalization for HF, acute coronary events, or ischemic stroke. Gastelurrutia et al 35 also observed reduced mortality in a HFREF population in an observational study.
In comparison with the above observational studies, the present study may be more unselective and generalizable because patients were included from 86% of all Swedish hospitals.
Thus, we confirm previous smaller and less well-adjusted observational studies because our results are in contrast to major recent RCTs.
The major RCTs 20, 21 have not shown a benefit from, and hence HF guidelines do not recommend statin use in HFREF (class III). However, both the AHA/ACC and the ESC guidelines on treatment of IHD state that statin treatment is recommended and they do not make exceptions for or qualify recommendations based on HFREF. [37] [38] [39] The well-established benefits of statins in IHD and diabetes mellitus may have made clinicians reluctant to include such patients in CORONA and GISSI and risk assignment to placebo, which may have compromised generalizability of those RCTs. Although the RCTs did include a substantial proportion of patients with IHD, specifically patients with predominantly IHD and perhaps milder HF may nonetheless not have been cared for by clinicians participating in the HF RCTs and may have been excluded based on clinician recommendation or own preference, given the extensive knowledge, including in the general public, of the benefits of statins. Indeed, in GISSI-HF, 21 only 57% of those ACEI/ARB indicates angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; DCM, dilated cardiomyopathy; IHD, ischemic heart disease; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; NYHA, New York Heart Association functional class; and RCT, randomized controlled trial.
Ellipsis are based on missing information from the original publication. No ANOVA tests have been performed because the original data from the 2 RCTs were not at hand.
screened were randomized, and the corresponding figure is not given in CORONA. 20 The 2 RCTs included considerable proportions with IHD and there was no interaction between statin treatment and IHD, but as alluded to, many patients with HFREF and IHD may have been excluded from these RCTs. In contrast, there was a strong interaction with statin use in our study (P=0.001), where the HR was 0.76 (P<0.001) with IHD and 0.95 (P=0.430) without IHD. Taken together, these observations and recommendation in guidelines, other than those for HF, suggest that the question of statin use in patients with concomitant IHD and HFREF may not be resolved.
Limitations
An observational registry-based study is subject to bias and confounding. Our study entails propensity score matching and adjustment for most variables that may affect the choice to prescribe a statin (bias) and affect outcome independent of statins (confounding). A standardized difference between groups of ≤10% is generally considered inconsequential. 40 Of all the 42 variables, only 1 had a standardized difference of >10% (EF, somewhat lower in the untreated patients, standardized difference 11%). Importantly, we cannot rule out residual confounding from unknown or unmeasured variables. The present study should merely be viewed as additional information on generalizability of RCTs and the potential role of statins in HFREF and concomitant IHD and in no way dictate treatment decisions.
Conclusions
In this large nationwide observational study of patients with HFREF, statins were associated with reduced all-cause mortality, cardiovascular mortality, cardiovascular hospitalization, and combined all-cause mortality and HF hospitalization. This contrasts with previous neutral RCTs. There was an interaction with IHD, suggesting potentially reduced mortality in patients with but not without IHD. Our findings in no way support the use of statins but do suggest that RCTs with more generalized inclusion and focused on presence and severity of IHD may be warranted.
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CLINICAL PERSPECTIVE
Statins improve outcomes in patients with ischemic heart disease (IHD) and are recommended in guidelines. Observational studies have suggested that they may be beneficial in heart failure not only in the presence but also in the absence of IHD. This hypothesis could not be confirmed in 2 randomized controlled trials, 20, 21 where statins in heart failure with reduced ejection fraction did not improve outcomes, regardless of presence of IHD, and heart failure guidelines do not recommend statins now. Questions remain about the generalizability of the trials and how to confront the conflicting evidence and recommendations in IHD. We performed a large observational study in the Swedish Heart Failure Registry, where associations between statin use and outcomes were assessed in 21 864 patients with heart failure with reduced ejection fraction, with matching by and adjustment for propensity scores for statin use. We observed that statin use was associated with reduced allcause mortality, cardiovascular mortality, heart failure hospitalization, and combined all-cause mortality or cardiovascular hospitalization. Statins were associated with reduced mortality in patients with but not without IHD. Given previous trials, our findings do not support general use of statins in heart failure with reduced ejection fraction, but whether statins may be beneficial in broader generalized populations, in particular with IHD, require further study.
